Legal & General Group PLC Outlook Therapeutics, Inc. Transaction History

Legal & General Group PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.2 - $1.78 $472 - $4,207	-2,364 Reduced 12.47%	16,590 $3,000
Q2 2023 Aug 14, 2023	SELL	$1.02 - $1.89 $48 - $90	-48 Reduced 0.25%	18,954 $32,000
Q1 2023 May 15, 2023	BUY	$1.0 - $1.35 $6,621 - $8,938	6,621 Added 53.48%	19,002 $20,000
Q1 2022 May 16, 2022	BUY	$1.22 - $2.03 $3,805 - $6,331	3,119 Added 33.68%	12,381 $22,000
Q2 2021 Aug 12, 2021	BUY	$1.78 - $2.76 $16,486 - $25,563	9,262 New	9,262 $23,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.